Coronado Biosciences Inc.
This article was originally published in Start Up
Executive Summary
Coronado Biosciences in-licenses and develops cancer drugs. One of its candidates is apogossypol, an inhibitor of Bcl-2 proteins that play a role in programmed cell death--a process that cancer cells manage to circumvent. Also in the start-up's pipeline: a less-toxic anthracycline and an agent that activates natural killer cells against residual cancer cells following treatment.